Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen Pharmaceutical for Development of Ophthalmic Treatments
5/3/2010 9:30:50 AM
NEWTON, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), and Santen Pharmaceutical Co., Ltd. (Osaka Stock Exchange: 4536), today announced that Santen has exercised its option to license Clinical Data’s highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.